Table 2.
NKC allele and genotype frequencies in healthy controls and melanoma patients.
| NK CRegion | Genotype | Controls (N = 200) | Melanoma Patients (N = 233) | ||
|---|---|---|---|---|---|
| Total | SSM | NM | |||
| NKC3 | CC | 83 (42%) | 114 (49%) | 81 (50%) | 13 (45%) |
| CG | 86 (43%) | 94 (40%) | 62 (38%) | 14 (48%) | |
| GG | 31 (15%) | 25 (11%) | 19 (12%) | 2 (7%) | |
| C-allele | 169 (85%) | 208 (89%) | 143 (88%) | 27(93%) | |
| NKC4 | GG | 111 (56%) | 138 (59%) | 97 (60%) | 15 (52%) |
| AG | 72 (36%) | 85 (37%) | 58 (36%) | 13 (45%) | |
| AA | 17 (8%) | 10 (4%) | 7 (4%) | 1 (3%) | |
| G-allele | 183(92%) | 223 (96%) | 155 (96%) | 28 (97%) | |
| NKC7 | AA | 28 (14%) | 22 (9%) | 17 (11%) | 2 (7%) |
| AT | 92 (46%) | 94 (40%) | 62 (38%) | 14 (48%) | |
| TT | 80 (40%) | 117 (51%) 1 | 83 (51%) 2 | 13 (45%) | |
| A-allele | 120 (60%) | 116 (49%) 3 | 79 (49%)4 | 16 (55%) | |
| NKC9 | AA | 16 (8%) | 27 (12%) | 21 (13%) | 3 (10%) |
| AG | 70 (35%) | 58 (25%) 5 | 38 (23%) 6 | 9 (31%) | |
| GG | 114 (57%) | 148 (63%) | 103 (64%) | 17 (59%) | |
| G-allele | 184 (92%) | 206 (88%) | 141 (87%) | 26 (90%) | |
| NKC10 | AA | 14 (7%) | 9 (4%) | 7 (4%) | 1 (3%) |
| AT | 75 (38%) | 76 (33%) | 53 (33%) | 10 (35%) | |
| TT | 111 (55%) | 148 (63%) | 102 (63%) | 18 (62%) | |
| T-allele | 186 (93%) | 155 (96%) | 155 (96%) | 28 (97%) | |
| NKC11 | CC | 80 (40%) | 109 (47%) | 79 (49%) | 12 (41%) |
| CT | 91 (46%) | 99 (42%) | 63 (39%) | 15 (52%) | |
| TT | 29 (14%) | 25 (11%) | 20 (12%) | 2 (7%) | |
| T-allele | 120 (60%) | 124 (53%) | 83 (51%) | 17 (59%) | |
| NKC12 | CC | 32 (16%) | 35 (15%) | 26 (16%) | 3 (10%) |
| CG | 87 (44%) | 100 (43%) | 64 (40%) | 17 (59%) | |
| GG | 81 (40%) | 98 (42%) | 72 (44%) | 9 (31%) | |
| C-allele | 119 (60%) | 135 (58%) | 90 (56%) | 20 (69%) | |
| NKC17 | CC | 35 (17%) | 43 (18%) | 32 (20%) | 7 (24%) |
| CG | 89 (45%) | 112 (48%) | 73 (45%) | 14 (48%) | |
| GG | 76 (38%) | 78 (34%) | 57 (35%) | 8 (28%) | |
| C-allele | 124 (62%) | 155 (66%) | 105 (65%) | 21 (72%) | |
SSM: superficial spreading melanoma; NM: nodular melanoma. 1,2 Total melanoma patients or SSM vs. control (p = 0.042, Pc = 1.01, OR = 1.51; p = 0.026, Pc = 0.62, OR = 0.62, respectively). 3 Melanoma patients vs. control (p = 0.042, Pc = 0.34, OR = 0.66). 4 SSM vs. control (p = 0.03, Pc = 0.24, OR = 0.6). 5,6 Total melanoma patients or SSM vs. control (p = 0.03, Pc = 0.72, OR = 1.5; p = 0.021, Pc = 0.50, OR = 0.6). p-value was determined by two-sided Fisher’s exact test.